« Back to Record
Citation APA

Baselga, J., Haddad, T., Ciruelos Gil, E. M., Vuylsteke, P., Ebbinghaus, S., Im, E., Eaton, L., Pathiraja, K., Gause, C., Mauro, D., Jones, M. B., Morales, S., Rugo, H., Awada, A., Blum, J. J., Tan, A. R., Ewertz, M., Cortes, J., Moy, B., & Ruddy, K. K. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast cancer research and treatment, 163(3), 535-544. doi:10.1007/s10549-017-4199-3


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/253468

Baselga, J., Haddad, T., Ciruelos Gil, E. M., Vuylsteke, P., Ebbinghaus, S., Im, E., Eaton, L., Pathiraja, K., Gause, C., Mauro, D., Jones, M. B., Morales, S., Rugo, H., Awada, A., Blum, J. J., Tan, A. R., Ewertz, M., Cortes, J., Moy, B., & Ruddy, K. K. (2017). A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast cancer research and treatment, 163(3), 535-544. doi:10.1007/s10549-017-4199-3